Clinical Trial Update: Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing single-agent ofatumumab with single-agent rituximab in indolent B-cell non-Hodgkin lymphoma relapsed after rituximab therapy; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Ofatumumab (ofatumumab)
• Rituximab (rituximab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Hodgkin's Lymphoma | Phase 3 | Status: TERMINATED | Results posted: 2018-05-16